Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

PURPOSE To compare the accuracy of computed tomography-(CT) scan and the radiolabeled glucose analog 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) visually correlated with CT (PET + CT) in the locoregional lymph node (LN) staging of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Sixty-eight patients with potentially operable NSCLC underwent thoracic CT, PET, and invasive surgical staging (ISS). Imaging studies were read prospectively and blinded to the surgical and pathologic data. A five-point visual scale was used for the interpretation of LNs on PET. Afterwards, with knowledge of the pathology, the relationship between standardized uptake values (SUVs) and the presence of metastasis in LNs was explored in a receiver operating characteristic (ROC) analysis, and the likelihood ratios (LRs) for SUVs of LNs were determined. RESULTS ISS was available for 690 LN stations. CT correctly identified the nodal stage in 40 of 68 patients (59%), with understaging in 12 patients and overstaging in 16 patients. PET + CT was accurate in 59 patients (87%), with understaging in five patients and overstaging in four patients. In the detection of locally advanced disease (N2/N3), the sensitivity, specificity, and accuracy of CT were 75%, 63%, and 68%, respectively. For PET + CT, this was 93%, 95%, and 94% (P = .0004). In the ROC curve, the best SUV threshold to distinguish benign from malignant LNs was 4.40. The analysis with this SUV threshold was not superior to the use of a five-point visual scale. The LR of a SUV less than 3.5 in an LN was 0.152; for a SUV between 3.5 and 4.5, it was 3.157; and for a SUV greater than 4.5, it was 253.096. CONCLUSION PET + CT is significantly more accurate than CT alone in LN staging of NSCLC. A five-point visual scale is as accurate as the use of an SUV threshold for LNs in the distinction between benign and malignant nodes. The very high negative predictive value of mediastinal PET could reduce the need for mediastinal ISS in NSCLC substantially.

[1]  E. Carlens Mediastinoscopy: a method for inspection and tissue biopsy in the superior mediastinum. , 1959, Diseases of the Chest.

[2]  J. R. Beck,et al.  Likelihood ratios. Another enhancement of sensitivity and specificity. , 1986, Archives of pathology & laboratory medicine.

[3]  H. Ransdell,et al.  Diagnostic anterior mediastinotomy. , 1966, The Annals of thoracic surgery.

[4]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose , 1994 .

[5]  I. Leav,et al.  The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. , 1996, Nuclear medicine and biology.

[6]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Delbeke,et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.

[8]  M. Mandelkern,et al.  Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. , 1996, American journal of respiratory and critical care medicine.

[9]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[10]  M. Decramer,et al.  Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  U. Pastorino,et al.  Pretreatment minimal staging for non-small cell lung cancers: a consensus report , 1991 .

[12]  M E Phelps,et al.  Whole-Body Positron Emission Tomography and Fluorodeoxyglucose , 2006 .

[13]  T. Naruke,et al.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer. , 1978, The Journal of thoracic and cardiovascular surgery.

[14]  H. Woodard,et al.  Letter: Expression of tissue isotope distribution. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[16]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[17]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[18]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[19]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[20]  Nohl-Oser Hc An investigation of the anatomy of the lymphatic drainage of the lungs as shown by the lymphatic spread of bronchial carcinoma. , 1972 .

[21]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[22]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R Iwata,et al.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[25]  J. Sunderland,et al.  Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. , 1996, The Journal of thoracic and cardiovascular surgery.

[26]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[27]  V. Lowe,et al.  Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. , 1995, Chest.

[28]  N. Gupta,et al.  PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. , 1995, Chest.